Cartesian Therapeutics (RNAC) Return on Equity (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Return on Equity for 10 consecutive years, with 1.69% as the latest value for Q4 2025.
- On a quarterly basis, Return on Equity fell 1038.0% to 1.69% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.69%, a 1038.0% decrease, with the full-year FY2025 number at 1.96%, up 161.0% from a year prior.
- Return on Equity was 1.69% for Q4 2025 at Cartesian Therapeutics, down from 4.36% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 12.07% in Q4 2024 to a low of 7.19% in Q4 2021.
- A 5-year average of 1.49% and a median of 0.4% in 2023 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: tumbled -32570bps in 2021, then skyrocketed 1165bps in 2024.
- Cartesian Therapeutics' Return on Equity stood at 7.19% in 2021, then skyrocketed by 103bps to 0.24% in 2022, then surged by 79bps to 0.42% in 2023, then soared by 2757bps to 12.07% in 2024, then crashed by -86bps to 1.69% in 2025.
- Per Business Quant, the three most recent readings for RNAC's Return on Equity are 1.69% (Q4 2025), 4.36% (Q3 2025), and 6.52% (Q2 2025).